Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib

References

• ApperleyJF2007Mechanisms of resistance to imatinib in chronic myeloid leukaemia (part I and II)Lancet Oncol810182917976612
   PubMed Web of Science ®Google Scholar
• AzamMRazTNardiV2003A screen to identify drug resistance variants to target directed anti-cancer agentsBiol Proced Online52041014615817
   PubMedGoogle Scholar
• BaccaraniMSaglioGGoldmanJ2006European Leukemia NetEvolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia NetBlood10818092016709930
   PubMed Web of Science ®Google Scholar
• BaccaraniMPaneFSaglioG2008Monitoring treatment of chronic myeloid leukemiaHaematologica93161918245647
   PubMed Web of Science ®Google Scholar
• BradeenHAEideCAO’HareT2006Comparison of imatinib mesylate, dasatinib and nilotinib in a N-Ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinationsBlood1082332816772610
   PubMed Web of Science ®Google Scholar
• CoolsJMentensNFuretP2004Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly target therapy of acute leukemiaCancer Res646385915374944
   PubMed Web of Science ®Google Scholar
• CortesJO’BrienSJabbourE2007Efficacy of nilotinib in patients with newly diagnosed, previously untreated Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase [abstract]Blood110 abstract 29
   Web of Science ®Google Scholar
• DonatoNJWuJYStapleyJ2003BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukaemia cells selected for resistance to STI571Blood101690812509383
   PubMed Web of Science ®Google Scholar
• DeiningerMBuchdungerEDrukerBJ2005The development of imatinib as a therapeutic agent for chronic myeloid leukaemiaBlood10526405315618470
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienS2006IRIS investigatorsFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med35524081717151364
   PubMed Web of Science ®Google Scholar
• ErnstTErbenPMullerMC2008Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinibHaematologica931869218223278
   PubMed Web of Science ®Google Scholar
• FaderlSTalpazMEstrovZ1999Chronic myelogenous leukaemia: biology and therapyAnn Intern Med1312071910428738
   PubMed Web of Science ®Google Scholar
• GilesFLarsonRAKantarjianH2007Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia in blast crisis who are resistant or intolerant to imatinib [abstract]Blood110 abstract 1025
   Web of Science ®Google Scholar
• GoldmanJMMeloJV2003Chronic myeloid leukaemia-advances in biology and new approaches to treatmentN Engl J Med34914516414534339
   PubMed Web of Science ®Google Scholar
• GolemovicMVerstovsekSGilesF2005AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, has in vitro activity against imatinib-resistant chronic myeloid leukaemiaClin Cancer Res114941716000593
   PubMed Web of Science ®Google Scholar
• GuoTAgaramNPWongGC2007Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumourClin Cancer Res1348748117699867
   PubMed Web of Science ®Google Scholar
• HochhausALa RoseeP2004Imatinib therapy in chronic myelogenous leukaemia: strategies to avoid and overcome resistanceLeukemia1813213115215876
   PubMed Web of Science ®Google Scholar
• HochhausAErbenPErnstT2007Resistance to targeted therapy in chronic myelogenous leukemiaSemin Hematol44S15S2417292737
   PubMed Web of Science ®Google Scholar
• HubbardSRWeiLEllisL1994Crystal structure of the tyrosine kinase domain of the human insulin receptorNature372746547997262
   PubMed Web of Science ®Google Scholar
• J⊘rgensenHGAllanEKJordanidesNE2007Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cellsBlood1094016917213283
   PubMed Web of Science ®Google Scholar
• KantarjianHMTalpazMO’BrienS2003Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaBlood1014737512393385
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFWunderleL2006Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLN Engl J Med35425425116775235
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFGattermannN2007aNilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceBlood1103540617715389
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSTalpazM2007bOutcome of patients with Philadelphia chromosome positive chronic myelogenous leukaemia post-imatinib mesylate failureCancer10915566017342766
   PubMed Web of Science ®Google Scholar
• KonigHHoltzMModiH2008Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signal-ling pathways or increased growth suppression in CML progenitorsLeukemia227485518273048
   PubMed Web of Science ®Google Scholar
• La Rosee’PHolm-EriksenSKonigH2008Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinibHaematologica93765918367481
   PubMed Web of Science ®Google Scholar
• Le CoutrePHochhausAHeimD2006A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosinophilic syndrome (HES) [abstract]Blood108 abstract 4912
   Web of Science ®Google Scholar
• Le CoutrePOttmannOGGilesF2008Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaBlood1111834918048643
   PubMed Web of Science ®Google Scholar
• LiuYGrayNS2006Rational design of inhibitors that bind to inactive kinase conformationsNat Chem Biol235836416783341
   PubMed Web of Science ®Google Scholar
• ManleyPWCowan-JacobSWFendrichG2004Urea derivatives of STI571 as inhibitors of BCR-ABL and PDGFR kinasesBioorg Med Chem Lett145793715501042
   PubMed Web of Science ®Google Scholar
• ManleyPWCowan-JacobSWFendrichG2005Molecular interactions between the highly selective pan-BCR-ABL inhibitor, AMN107, and the tyrosine kinase domain of AblBlood106940a
   Web of Science ®Google Scholar
• MarinDGoldmanJMOlavarriaEApperleyJF2003Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional dosesBlood1022702314504074
   PubMed Web of Science ®Google Scholar
• O’HareTWaltersDKStoffregenEP2005In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsCancer Res654500515930265
   PubMed Web of Science ®Google Scholar
• RayACowan-JacobSWManleyPW2007Identification of Bcr/Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 by a random mutagenesis studyBlood1095011517303698
   PubMed Web of Science ®Google Scholar
• SattlerMGriffinJD2003Molecular mechanisms of transformation by the BCR-ABL oncogeneSemin Hematol4041012783368
   PubMed Web of Science ®Google Scholar
• SchindlerTBommannWPellicenaP2000Structural mechanism for STI571 inhibition of abelson tyrosine kinaseScience28919384210988075
   PubMed Web of Science ®Google Scholar
• StoverEHChenJLeeBH2005The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivoBlood10632061316030188
   PubMed Web of Science ®Google Scholar
• VerstovsekSAkinCManshouriT2006aEffects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kitLeuk Res3013657016797704
   PubMed Web of Science ®Google Scholar
• VerstovsekSGilesFQuintas-CardamaA2006bActivity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFRalpha-expressing cellsLeuk Res30149950516682077
   PubMed Web of Science ®Google Scholar
• Von BubnoffNManleyPWMestanJ2006BCR-ABL resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinibBlood10813283316614241
   PubMed Web of Science ®Google Scholar
• Von BubnoffNGorantlaSPThoneS2006The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107Blood1074970216754777
   PubMed Web of Science ®Google Scholar
• WeisbergEManleyPWBreitensteinW2005Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABLCancer Cell71294115710326
   PubMed Web of Science ®Google Scholar
• WeisbergECatleyLWrightRD2007Beneficial effects of combining imatinib and nilotinib in preclinical models of BCR-ABL+ leukemiasBlood10921122017068153
   PubMed Web of Science ®Google Scholar
• WhiteDLSaundersVAQuinnSR2007Imatinib increases the intracellular concentrations of nilotinib, which may explain the observed synergy between these drugsBlood10936091017409347
   PubMed Web of Science ®Google Scholar
• ZonderJAPembertonPBrandtH2003The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatmentClin Cancer Res92092712796373
   PubMed Web of Science ®Google Scholar